Your Current Position: NEWS > Company News
-
Oct. 19, 2018. Professor Michel L. Tremblay from McGill University visited Converd and had a proactive communication with our scientists.
-
【Company News】 Wu Weizhong, Director of the Institute of Liver Cancer, Zhongshan Hospital, visited Converd2018-07-05Wu Weizhong, the Director of the Institute of Liver Cancer and Deputy Director of Cell Therapy Research Center of Zhongshan Hospital affiliated to Fudan University
-
【Company News】 Nanjing Legend Biotechnology Company's Chief Strategy Officer Dr. Zhu Li visited Converd2018-07-05Dr Zhu Li, the Chief Strategy Officer of Nanjing Legend Biotechnology Co., visited Converd and had in-depth communication with Dr. Hu Fang, Chairman of Converd,
-
【Company News】 Converd’s clinical trial of using oncolytic virus in combination with immunotherapy for gastrointestinal cancers2018-04-30Converd has initiated a phase I/II clinical trial: A Combination Study to Evaluate the Safety and Efficacy of an Anti-cancer agent (A01) with Immune Cells (IC01) in patients with Advanced Gastrointestinal Cancer.
-
【Company News】 A clinical study of CAR-NK for treatment of metastatic solid tumors is conducted by Converd’s subsidiary, Hangzhou Youshan Sictech Ltd.2018-04-30This clinical study has started in the in the 3rd hospital of Guangzhou Medical University. It is designed to evaluate safety and efficacy of a novel CAR-NK cell therapy for patients with an advanced cancer.
-
【Company News】 Deputy Dean Xv Xuehu and Director Sheng Xiujie of the Third Affiliated Hospital of Guangzhou Medical University came to Converd for academic exchange2018-02-22On January 13, 2018, Deputy Dean Xv Xuehu and Director Sheng Xiujie of the Third Affiliated Hospital of Guangzhou Medical University came to our company for academic exchanges.
-
【Company News】 Dean Zhong Zhengxiang and Doctor Bao Yi of Jiaxing 2nd Hospital came to Converd for academic exchange2018-02-22On February 3, 2018, Dr. Zhong Zhengxiang and Dr. Bao Zheng from Jiaxing 2nd Hospital came to our company for academic exchanges.
-
Converd has completed and moved to its new R & D center in Hangzhou. The Center holds 1,000 m2 area of laboratory space for Molecular and Cellular biology
-
【Company News】 Converd forms a partnership with China Resources (CR Pharmaceutical) in developing oncolytic virus therapy platform2017-12-15Converd has received investment in shares from CR Pharmaceutical(华润生命科学). This is a part of Converd’s B series financing, which also includes investments from Nanjing Jingyong Healthcare Capitals.
-
Professor Gao Daiqing came to our company for academic exchange on clinical research of immunotherapy.